COMMUNIQUÉS West-GlobeNewswire

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
02/05/2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic [...]
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/05/2024
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation DOYLESTOWN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “ [...]
KFSH&RC Ranked Top Valuable Healthcare Brand in Saudi Arabia and Middle East
02/05/2024
RIYADH, Saudi Arabia, May 02, 2024 (GLOBE NEWSWIRE) -- KFSH&RC tops the healthcare sector in the Kingdom of Saudi Arabia and the Middle East, recognizing it as the most valuable healthcare brand in these regions for [...]
Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
02/05/2024
– Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO ALTO, Calif. and RESEARCH [...]
Outlook Therapeutics® to Present at the Retina World Congress 2024
02/05/2024
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment [...]
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
02/05/2024
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab . The findings will deepen understanding [...]
GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION
02/05/2024
Continuous blood glucose monitor’s preclinical data and sensor longevity modeling to be presented at major diabetes conference Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“ [...]
Cerevance Achieves First Milestone in Research Collaboration with Merck
02/05/2024
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced the achievement of the first milestone in its [...]
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
02/05/2024
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and [...]
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
02/05/2024
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered [...]
QHSLab, Inc. Enhances Leadership Team with Dr. Marcos Sanchez-Gonzalez as New VP of Medical and Scientific Affairs
02/05/2024
WEST PALM BEACH, FL, May 02, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based [...]
Veru to Present at the GLP-1 Based Therapeutics Summit
02/05/2024
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
02/05/2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will [...]
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
02/05/2024
Reports record revenue of $17.6 million for the first quarter of 2024. Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. Reports first quarter of 2024 operating income of [...]
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
02/05/2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results [...]
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
02/05/2024
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company's drug-drug [...]
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
02/05/2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs [...]
Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer
02/05/2024
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics for cancer and [...]
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
02/05/2024
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early [...]

Pages